Chiron Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Bayer Corp.' s $1.1 bil. cash acquisition of the unit has been finalized, parent Chiron reports Nov. 30. Originally announced on Sept. 17, the deal includes Chiron's immunodiagnostic, critical care, nucleic acid diagnostic and chemistry businesses, but not the blood testing business ("The Gray Sheet" Sept. 21, p. 13)